Mediwound Ltd (NASDAQ:MDWD) Sees Significant Decline in Short Interest

Share on StockTwits

Mediwound Ltd (NASDAQ:MDWD) was the recipient of a large decline in short interest in the month of June. As of June 30th, there was short interest totalling 173,100 shares, a decline of 5.2% from the May 30th total of 182,600 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average daily trading volume, of 81,700 shares, the days-to-cover ratio is currently 2.1 days.

MDWD has been the topic of several analyst reports. Oppenheimer set a $22.00 price target on shares of Par Pacific and gave the company a “buy” rating in a report on Monday, March 25th. Zacks Investment Research lowered shares of Farmland Partners from a “hold” rating to a “sell” rating in a report on Friday. Finally, ValuEngine lowered shares of Virtu Financial from a “hold” rating to a “sell” rating in a report on Tuesday, June 18th.

Mediwound stock remained flat at $$3.11 on Tuesday. 857 shares of the company’s stock traded hands, compared to its average volume of 60,551. The stock has a market cap of $84.53 million, a PE ratio of -6.35 and a beta of 0.58. The company has a quick ratio of 3.79, a current ratio of 3.99 and a debt-to-equity ratio of 0.40. The business’s 50 day moving average price is $3.62. Mediwound has a 12-month low of $3.00 and a 12-month high of $6.75.

Mediwound (NASDAQ:MDWD) last posted its earnings results on Tuesday, May 21st. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.01). Mediwound had a negative return on equity of 383.19% and a negative net margin of 18.43%. The firm had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.60 million. On average, research analysts forecast that Mediwound will post -0.59 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Delek Group Ltd. bought a new stake in shares of Mediwound in the 1st quarter worth about $141,000. Meitav Dash Investments Ltd. grew its holdings in Mediwound by 0.6% during the 1st quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock worth $2,993,000 after acquiring an additional 3,536 shares during the last quarter. Deutsche Bank AG grew its holdings in Mediwound by 73.5% during the 4th quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 16,840 shares during the last quarter. Menta Capital LLC grew its holdings in Mediwound by 200.2% during the 1st quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 29,686 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Mediwound by 33.2% during the 4th quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock worth $278,000 after acquiring an additional 17,048 shares during the last quarter. 30.78% of the stock is currently owned by institutional investors and hedge funds.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

See Also: Different Options Trading Strategies

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.